As PD-1 expression in T cells and PD-L1 in MM cells contribute to relapse and drug resistance mechanisms, immune-based therapeutic strategies that target checkpoint signaling with anti-PD-1 mAb could inhibit tumor cell growth and restore immune function [75]. The gene discussed is CD274; the disease is Miyoshi myopathy.